Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review
Carcinoma ex pleomorphic adenoma (CXPA) is an epithelial malignancy that transforms from benign pleomorphic adenomas (PA) at a rate of 1.5% after 5 years and 10% after 15 years. The average age of reported nasopharyngeal CXPA is 56.7 years. However, the present case describes a 19-year-old making th...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Case Reports in Otolaryngology |
Online Access: | http://dx.doi.org/10.1155/2021/8892280 |
id |
doaj-9c567687dd9d4005a70d0fcce3361fcb |
---|---|
record_format |
Article |
spelling |
doaj-9c567687dd9d4005a70d0fcce3361fcb2021-03-08T02:01:14ZengHindawi LimitedCase Reports in Otolaryngology2090-67732021-01-01202110.1155/2021/8892280Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature ReviewEllen L. Tokarz0Adian A. Ong1Mark S. Burke2State University of New York at BuffaloState University of New York at BuffaloState University of New York at BuffaloCarcinoma ex pleomorphic adenoma (CXPA) is an epithelial malignancy that transforms from benign pleomorphic adenomas (PA) at a rate of 1.5% after 5 years and 10% after 15 years. The average age of reported nasopharyngeal CXPA is 56.7 years. However, the present case describes a 19-year-old making this case exceptionally rare. Standard treatment is wide local excision with adjuvant treatment. We report the demographics, presentation, treatment, and outcomes of 8 cases of nasopharyngeal CXPA. While surgical excision is the mainstay of treatment, negative margins can be difficult to obtain at the skull base, and we report a recurrence rate of 50% in nasopharyngeal primaries. Due to the aggressive nature of the disease and high rate of recurrence, the majority of patients in our review received adjuvant radiation with some receiving adjuvant chemotherapy in addition.http://dx.doi.org/10.1155/2021/8892280 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ellen L. Tokarz Adian A. Ong Mark S. Burke |
spellingShingle |
Ellen L. Tokarz Adian A. Ong Mark S. Burke Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review Case Reports in Otolaryngology |
author_facet |
Ellen L. Tokarz Adian A. Ong Mark S. Burke |
author_sort |
Ellen L. Tokarz |
title |
Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review |
title_short |
Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review |
title_full |
Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review |
title_fullStr |
Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review |
title_full_unstemmed |
Nasopharyngeal Carcinoma Ex Pleomorphic Adenoma: Case Report and Comprehensive Literature Review |
title_sort |
nasopharyngeal carcinoma ex pleomorphic adenoma: case report and comprehensive literature review |
publisher |
Hindawi Limited |
series |
Case Reports in Otolaryngology |
issn |
2090-6773 |
publishDate |
2021-01-01 |
description |
Carcinoma ex pleomorphic adenoma (CXPA) is an epithelial malignancy that transforms from benign pleomorphic adenomas (PA) at a rate of 1.5% after 5 years and 10% after 15 years. The average age of reported nasopharyngeal CXPA is 56.7 years. However, the present case describes a 19-year-old making this case exceptionally rare. Standard treatment is wide local excision with adjuvant treatment. We report the demographics, presentation, treatment, and outcomes of 8 cases of nasopharyngeal CXPA. While surgical excision is the mainstay of treatment, negative margins can be difficult to obtain at the skull base, and we report a recurrence rate of 50% in nasopharyngeal primaries. Due to the aggressive nature of the disease and high rate of recurrence, the majority of patients in our review received adjuvant radiation with some receiving adjuvant chemotherapy in addition. |
url |
http://dx.doi.org/10.1155/2021/8892280 |
work_keys_str_mv |
AT ellenltokarz nasopharyngealcarcinomaexpleomorphicadenomacasereportandcomprehensiveliteraturereview AT adianaong nasopharyngealcarcinomaexpleomorphicadenomacasereportandcomprehensiveliteraturereview AT marksburke nasopharyngealcarcinomaexpleomorphicadenomacasereportandcomprehensiveliteraturereview |
_version_ |
1714797278340841472 |